Orthocell (ASX:OCC) has joined a cohort of Australian life sciences companies seeking to calm investor nerves over looming US tariff measures, arguing that its business will remain largely untouched even as Washington signals a tougher stance on imported pharmaceuticals.

Mesoblast (ASX:MSB) has received clearance from the US Food and Drug Administration to proceed directly to a registrational trial of its therapy, Ryoncil, in children with Duchenne muscular dystrophy.

The Board of MTPConnect has announced the appointment of Chief Executive Officer Stuart Dignam as a Director, marking a significant milestone as the organisation moves into its second decade of operation.

Telix Pharmaceuticals (ASX:TLX) has delivered robust revenue growth alongside meaningful progress across its therapeutics pipeline in the three months to the end of March 2026.

The company said it has begun reviewing the details of the announcement, with an initial assessment indicating that the majority of its product portfolio in the US market is unlikely to fall within the scope of the tariffs.

The Melbourne-based company had been studying narmafotinib in combination with the widely used but aggressive mFOLFIRINOX regimen in patients with advanced pancreatic cancer.

Vitura Health (ASX:VIT) has appointed experienced healthcare executive Justin James as its new chief executive officer, marking a significant leadership shift as the company positions itself for further expansion in emerging therapies and digital health services.

Algorae Pharmaceuticals (ASX:1AI) has moved to strengthen its financial footing, announcing a $3.9 million capital raise to scale its commercial operations and advance its artificial intelligence-driven research pipeline.

Clinuvel Pharmaceuticals (ASX:CUV) used one of the world’s largest dermatology forums to sharpen its profile in pigmentary disorders, presenting new clinical insights and reinforcing the positioning of its lead therapy across both approved and investigational uses.

Arovella Therapeutics (ASX:ALA) has reported new preclinical data that strengthens the case for its engineered immune cell platform, demonstrating sustained and enhanced killing of pancreatic and gastric cancer cells in laboratory studies.

In laboratory models of human neurons, NUZ-001 appears to activate multiple internal systems that clear misfolded and aggregated proteins, a hallmark of conditions such as amyotrophic lateral sclerosis.

Telix Pharmaceuticals (ASX:TLX) has moved to bolster its board and leadership succession plans with the appointment of veteran healthcare executive David Gill as a non-executive director.

In new data from ongoing investigator-initiated trials in China, the company’s experimental CAR-T therapy, BZDS1901, demonstrated tumour shrinkage and even complete clearance in a subset of heavily pretreated patients.

Paradigm Biopharmaceuticals (ASX:PAR) has announced a new research collaboration with City, University of London, aimed at unlocking deeper insights into how its lead therapy works at the biological level.

A new analysis has found that Australia’s medical research institutes are not only advancing science but also delivering substantial economic value and strengthening the nation’s healthcare capability.

Algorae Pharmaceuticals has taken another step in its push to transform drug discovery through artificial intelligence, deepening its collaboration with the Peter MacCallum Cancer Centre in a new program aimed at validating AI-predicted drug combinations.

Cynata Therapeutics has reached a pivotal moment in its clinical development journey, marking the completion of the 100-day primary evaluation period for all participants in its Phase 2 trial of CYP-001, a stem cell therapy targeting acute graft-versus-host disease.

The company announced that it has received encouraging feedback from the United States Food and Drug Administration following a recent Type C meeting, marking a significant moment in its clinical development journey.